Goal is to foster open collaboration between Lilly and global laboratory researchers
INDIANAPOLIS, June 15 /PRNewswire-FirstCall/ -- Alzheimer's disease. Cancer. Diabetes. Osteoporosis.
These are the diseases for which Eli Lilly and Company will be engaging researchers from around the world in a new and unique drug discovery initiative.
The initiative, called the Lilly Phenotypic Drug Discovery Initiative, or PD2 (pronounced PD-squared)*, uses Lilly-developed disease-state assays and a secure web portal to evaluate the therapeutic potential of compounds synthesized in university and biotechnology laboratories. Findings from this initiative could ultimately form the basis for collaboration or licensing agreements between Lilly and external institutions.
"Each year, researchers throughout the world design and synthesize compounds in university and biotechnology laboratories that are never fully evaluated as potential drug candidates," said Alan D. Palkowitz, Ph.D., vice president of discovery chemistry research and technologies at Lilly. "There's an untapped source of ideas and compounds in the greater scientific community that could ultimately impact patients' lives following further evaluation and development."
Collaborations between Lilly and external researchers are not new; however, the PD2 initiative is designed to provide a more convenient point of entry for global external researchers into Lilly's drug discovery and development process. By doing so, PD2 allows for the establishment of productive relationships with institutions and organizations that may not previously have worked with Lilly.
"Increasingly, innovation depends on a broad network of relationships outside our walls," said Palkowitz, adding that PD2 is yet another example of Lilly's evolving transformation from a Fully Integrated Pharmaceutical Company, or FIPCO, to a Fully In
|SOURCE Eli Lilly and Company|
Copyright©2009 PR Newswire.
All rights reserved